CLARUS® textiles enable natural fibers—like recycled cotton—to meet new levels of performance. Think: the utility of synthetics from 100 percent natural sources. CLARUS® …

Dec 17, 2021 · This year NFW added 110,000 square feet of manufacturing space for MIRUM®, a categorically new, plant-based material perfect for footwear, fashion, automotive, and accessories. This new facility, which is housed on Jefferson Avenue in downtown Peoria, more than doubled NFW’s manufacturing footprint.

Here at Mirum, we see beyond rare diseases—we see the people. With creativity and heart, we light the way for those searching for hope. Because every breakthrough we make is not just medicine—it’s a moment of joy, a chance for patients to live fully.

Here at Mirum, we have brought together some of the top experts in liver disease, rare disease, and pharmaceutical development. It is with passion, insight, and collective experience that we’re pushing the boundaries of what is possible.

Jan 7, 2022 · 2022 is set to be a banner year for CLARUS®, our patented technology platform creating categorically new, all-natural, plastic-free performance textiles. We worked with our brand partner, Ralph Lauren, to create the first ever CLARUS apparel.

Feb 24, 2025 · Mirum Pharma's Ctexli has become the first FDA-approved therapy for cerebrotendinous xanthomatosis (CTX), an ultra-rare form of lipid storage disease.

Feb 24, 2025 · The Food and Drug Administration on Friday approved a drug from Mirum Pharmaceuticals to treat a rare genetic disorder that causes toxic depositions of fat in different organs of the body. Called Ctexli, the drug is cleared for adults cerebrotendinous xanthomatosis, or …

No-cost genetic testing for 66 genes associated with early onset, often bilateral, cataracts is being offered for qualifying US-resident patients through a program sponsored by Mirum Pharmaceuticals.

Jan 13, 2025 · Mirum Pharmaceuticals Inc (MIRM, Financial) has released its preliminary and unaudited estimates for full-year 2024 net product sales, year-end cash balance, and corporate updates, along with its outlook for 2025.

Mirum’s late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis.